User profiles for D. J. LOVELL
Lovell, DJVerified email at cchmc.org Cited by 28334 |
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for …
Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth birthday …
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth birthday …
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical …
The American College of Rheumatology (ACR) published treatment recommendations for
juvenile idiopathic arthritis (JIA) in 2011 (1). These recommendations represented the first …
juvenile idiopathic arthritis (JIA) in 2011 (1). These recommendations represented the first …
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …
>6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory …
[HTML][HTML] Etanercept in children with polyarticular juvenile rheumatoid arthritis
DJ Lovell, EH Giannini, A Reiff… - … England Journal of …, 2000 - Mass Medical Soc
Background We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis
factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid …
factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid …
Preliminary definition of improvement in juvenile arthritis
Objective. To identify a core set of outcome variables for the assessment of children with
juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine …
juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine …
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal‐onset multisystem inflammatory disease (NOMID): A …
…, K Schikler, H Hoffman, DJ Lovell… - Arthritis & …, 2002 - Wiley Online Library
Objective Neonatal‐onset multisystem inflammatory disease (NOMID; also known as chronic
infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, …
infantile neurologic, cutaneous, articular [CINCA] syndrome) is characterized by fever, …
2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American …
…, T Kitoh, K Lehmberg, DJ Lovell… - Arthritis & …, 2016 - Wiley Online Library
Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …
[HTML][HTML] Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …
arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF …
[HTML][HTML] Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …